To assess potential mechanisms of cortical superficial siderosis (cSS), a central MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative metaanalysis of APOE associations with cSS presence and severity.
Introduction
Cortical superficial siderosis (cSS) is detected as curvilinear hypointensities following the cortical surface on blood-sensitive T2*-weighted gradient-recalled echo (T2*-GRE) and susceptibility-weighted (SWI) MRI sequences. 1 It is generally thought that cSS reflects deposits of blood-breakdown products in the outermost cortical layers from, often occult, convexal subarachnoid hemorrhage. 1, 2 cSS is particularly common in advanced cerebral amyloid angiopathy (CAA) (prevalence 40-60%), 1, 3, 4 a small vessel disease that results from amyloid-β deposition in cortical and leptomeningeal arterioles. In CAA patients, cSS seems to be consistently associated with increased risk of incident 5 and recurrent 6 lobar intracerebral hemorrhage (ICH), including early recurrence, 7 as well as future dementia. 8 cSS is hence now considered a third cardinal hemorrhagic signature of CAA, 1, 9 alongside multiple strictly lobar cerebral microbleeds and lobar ICH. It is also included in the modified Boston criteria, as a specific MRI biomarker of the disease. 2 The emerging clinical relevance of cSS, either as direct contributor to CAA-related impairment or a biomarker of the disease's presence, severity and course, raises questions about the mechanisms of this imaging lesion. However, data from neuropathological studies remain extremely limited. Understanding the underlying mechanisms and vascular pathology contributing to cSS could be facilitated by identifying associations with Apolipoprotein E (APOE) alleles. Associations between APOE e2 or e4 alleles with both lobar ICH risk and CAA presence and severity on neuropathology have been previously described. In fact, APOE genotype seem to be the single most important genetic determinant of CAA pathophysiology, identified to date. 10, 11 The current hypothesis, albeit supported by limited data, is that APOE e4 enhances vascular amyloid-β deposition in a dose-dependent fashion, 12 while APOE e2 promotes, so-called, CAA-related vasculopathic changes (vessel cracking, detachment and delamination of the outermost layer of the tunica media and fibrinoid necrosis) which can lead to vessel rupture. 13 It is hypothesized that cSS results from bleeding-prone leptomeningeal or superficial cortical arterioles that harbour advanced CAA and associated vasculopathic changes. 1 To gain further insights into potential mechanisms of cSS in CAA and small vessel disease, we performed a collaborative meta-analysis of all available published studies that provided APOE data according to cSS presence and severity. Since cSS appears to convey high risk of recurrent ICH, it might segregate with APOE genotypes that are associated with CAA-related vasculopathic changes. Hence, we specifically tested the hypothesis that cSS presence and severity is associated with APOE e2, a marker of CAA-related small vessel fragility.
Methods

Standard Protocol Approvals, Registrations, and Patient Consents
The study was performed according to a predefined protocol (i.e. before collecting and analysing data) designed in house and finalised in January 2016. This report was prepared with reference to the PRISMA, 14 the MOOSE 15 guidelines and the Cochrane Handbook for Systematic Reviews of Interventions.
Study identification and selection criteria
We sought all studies of adult humans published in any language that reported APOE genotype data and had cSS assessment on MRI, regardless of whether any association between the two was reported. We searched PubMed and Embase (from inception to January 2016 and updated in November 2017) using a combination of keyword search and MeSH terms, i.e. ("cortical superficial siderosis" OR "convexity siderosis" OR "convexal siderosis" OR "cortical hemosiderosis" OR siderosis OR hemosiderosis) AND (APOE OR "apolipoprotein E"). We also screened the references lists of all relevant studies and reviews identified, and searched Google Scholar for other studies citing potentially eligible relevant studies. We included relevant studies with >20 participants, including studies that recruited individuals from three distinct settings: (a) patients presenting to stroke clinics with symptomatic sporadic CAA (i.e. lobar intracerebral haemorrhage, transient focal neurological episodes) according to the validated classic Boston criteria (i.e. cSS was not part of CAA diagnosis); (b) memory clinic patients; and (c) participants from population-based studies. The rationale for including individuals from these different clinical settings was twofold. First, they represent the most likely clinical scenarios in which cSS in small vessel disease is detected on MRI (a and b) and are of potential clinical significance. Second, they capture the spectrum of cardinal CAA phenotypes:
relatively "pure" stroke presentations (including lobar intracerebral haemorrhage), cognitive impairment/dementia, or incidental findings in elderly healthy populations.
We excluded case reports, small case series, and studies including hereditary/familial forms of CAA. Two authors independently selected eligible studies, resolving disagreements by discussion. When two or more studies with overlapping cohorts existed, we included only the study providing the most data about the association and the largest number of participants.
Data extraction
Eligible studies were classified according to the primary clinical setting as (a) symptomatic CAA; (b) memory clinics; or (c) population-based. For each included study, we extracted information using standard proformas on publication year, country in which the study was conducted, study design, participant source and baseline demographic/clinical characteristics.
For our planned meta-analyses, we extracted, or required from authors summary-level data on numbers of participants with each APOE genotype (i.e. e3e3, e2 e3, e3e4, e4e4, e2e2, e2e4) according to cSS presence and severity (focal or disseminated) where available.
A structured data extraction form was created and completed as far as possible by entering data from the relevant publication(s) and/or circulated to authors and a collaborative group was established. We also extracted information on the MRI sequence characteristics used for cSS detection and the rating methods used for cSS classification.
Quality and risk of bias assessment
We assessed each study against a list of quality criteria we devised based on study size, cohort recruitment method (prospective vs. other), blinding of cSS ratings and APOE genotype data, quality of genotyping, blood-sensitive MRI sequence type used, criteria of cSS assessment and inter-rater agreement. These criteria were created using elements with reference to the STREGA (Strengthening the Reporting of Genetic Association Studies) 16 , MOOSE (Metaanalysis of Observational Studies in Epidemiology) 15 recommendations and consensus standards for cSS assessment and rating. 1
Statistical analysis and synthesis
We performed meta-analyses using Stata 13.0 (StataCorp LP, Texas) and considered a p value of <0.05 to imply statistical significance. In our primary analyses, we calculated study-specific and random effects pooled, unadjusted ORs for cSS presence vs. absence among e4 allele carriers (e4+) versus the reference genotype e3e3 and among e2 carriers (e2+) versus the wild type e3e3. This comparison was selected, to avoid potential confounding by mixed effects of e2 and e4 in the comparison group. In secondary analyses, we compared cSS severity (focal vs. no cSS and disseminated vs. no cSS) in participants with an e2+ or e4+ genotype vs. the e3/e3 genotype. In analyses looking at cSS severity (i.e. focal or disseminated cSS) the comparison groups included only patients without cSS. Meta-analyses were performed both separately by study setting/population, and overall. In all analyses we used a random effects model with DerSimonian-Laird weights, 17 using odds ratios (OR) and their corresponding 95% CIs, with the inverse variance method for weighting. We assessed statistical heterogeneity using I-squared statistics and visually through inspection of the forest plot. Values of ≤25%, 25% to 50%, and ≥50% were defined as low, moderate, and high degrees of heterogeneity, respectively. We explored publication bias with funnel plots. As a subanalysis, and to reveal potential dose-effect relationships, we have also explored the association between all different APOE genotypes (i.e. e2 e3, e3e4, e4e4, e2e2, e2e4 vs. e3e3) and cSS presence and severity in the whole population and across different clinical settings. To assess robustness of the methods, we repeated all the above analyses using the fixed effects method.
Data availability statement
All relevant data and methods are reported in the manuscript. No data available in public repositories.
Results
Characteristics and quality of included studies
From 33 publications identified in our literature search, we identified 13 relevant studies fulfilling our inclusion criteria and pooled in meta-analyses ( Figure 1 ). Study populations comprised seven memory clinic cohorts (n=2587), five symptomatic non-overlapping CAA cohorts (n=402) and one population based study including healthy people (n=1379) ( Table 1) .
The memory clinic studies had different inclusion criteria and dementia prevalence ( Table 1) .
The symptomatic CAA studies included two cohorts presenting with stroke syndromes other than ICH, one with pure CAA-ICH, and two with both CAA-ICH and CAA non-ICH presentations. Four out of these five CAA cohorts were derived from different studies completed at the same centre, 4, 18-20 but included largely non-overlapping patient cohorts (i.e. different clinical settings/recruitment, clinical presentation, inclusion criteria, inception etc.).
In detail (see footnote in Table 1 ), one of these four single centre cohorts, 4 an advanced research MRI study of CAA-related ICH patients have included around 10% of overlapping patients with a separate consecutive clinical ICH cohort, 19 from which CAA-related lobar ICH were included in our analysis, based on our best estimates. This latter clinical CAA cohort 19 might have slightly overlapped (~10%) with a pathology-based cohort of CAA patients. 20 Mean age was between 63-75 years and about half of all participants were male. Most studies were conducted in predominantly white populations in centres from Europe, USA or Australia, while two studies were conducted on Asia. The distribution of the ethnicity of participants in each study was not available.
There was variation in overall study quality ( Table 2) , including sample size and retrospective vs. prospective designs. The genotyping quality was generally good when assessed against current reporting standards. Studies varied in the type of blood-sensitive sequences used for cSS detection (e.g. T2*-GRE vs. SWI), as well as MRI field strength, with all cohorts on symptomatic CAA patient populations using 1.5 T MRI, while memory clinic studies were performed at 3T MRI. The methods of cSS assessment were reliable and largely in line with current consensus recommendations in the field. 1 For details on quality assessment and individual scores of included studies in the meta-analysis, see Table 2 .
Pooled prevalence and severity of cSS in included studies
The pooled prevalence of cSS presence was 2% (95%CI: 2%-3%, I 2 : 59%, p=0.02) in memory clinic patients, 47% (95%CI: 38%-56%, I 2 : 66%, p=0.02) in symptomatic CAA patients and 1%
(95%CI: 1%-2%) in the single population-based study included in our analysis. The overall pooled prevalence of focal cSS in memory clinic vs. symptomatic CAA patients was 1% (95%CI:
1%-2%, I 2 : 48%, p=0.07) and 17% (95%CI: 13%-22%, I 2 : 24%, p=0.26) respectively. The overall pooled prevalence of disseminated cSS was 1% (95%CI: 0%-1%, I 2 : 9%, p=0.36) vs. 28% (95%CI:
20%-36%, I 2 : 60%, p=0.04) in memory clinic vs. symptomatic CAA cohorts respectively. In all comparisons, the prevalence of cSS (presence and severity) was higher in symptomatic CAA vs. memory clinic patients (p<0.0001). Among patients with any cSS, the prevalence of focal cSS was 67% (95%CI: 55%-79%, I 2 : 17%, p=0.30) in memory clinic patients and 37% (95%CI:
26%-49%, I 2 : 60%, p=0.04) in symptomatic CAA cases (p<0.001 between the two groups).
Meta-analyses: APOE e4 and e2 and cSS presence and severity
The results of the main analyses of the association between APOE e4 and e2 with cSS presence are summarised in Figure 2 . Compared to participants with an APOE e3/e3 genotype, pooled overall results showed no increased odds of cSS presence in participants with APOE e4+ genotype ( Figure 2A ). When stratified by clinical subgroups, APOE e4+
genotype was associated with cSS presence in memory clinic patients, but not symptomatic CAA patients (Figure 2A ). The pooled OR showed increased odds of having cSS for APOE e2+ genotypes (OR 2.67, 95%CI: 2.31-3.08) with no statistical heterogeneity between study results ( Figure 2B ). This association was strong in both memory clinic and symptomatic CAA cohorts ( Figure 2B ).
All clinical studies provided relevant data for meta-analyses of APOE genotypes and cSS severity (focal or disseminated). These data were not available to pool in the single populationbased study which reported on APOE and cSS. Overall, pooled results showed that, compared to patients with an e3/e3 genotype, those with an e4 + genotype did not have increased odds of having either focal or disseminated cSS ( Figure 3A ). Memory clinic patients showed only a non-significant trend for an association with APOE e4 + genotype and cSS burden ( Figure 3A ).
Overall, patients with APOE e2+ genotype had increased odds for an association with disseminated, but not focal, cSS ( Figure 3B ). When stratified by clinical setting, focal cSS was associated with APOE e2+ genotype in memory clinic patients, and showed a strong trend with disseminated cSS in this population ( Figure 3B ). In symptomatic CAA cohorts, only disseminated cSS was associated with APOE e2+ genotype. There was no evidence of publication bias and statistical heterogeneity was low to moderate across analyses (data provided in each forest plot)
Subgroup meta-analyses: different APOE genotypes and cSS presence and severity
The detailed results of subanalyses exploring the association between all different APOE genotypes (vs. e3/e3) and cSS presence and burden are summarised in Table 3 . In the overall analysis of all the cohorts together, the most consistent associations with higher effect sizes were seen with APOE e2/e2 and APOE e2/e4 genotypes ( Table 3) . The associations were different when stratified by the clinical setting. In memory clinic cohorts, cSS presence and severity was also associated with APOE e4/e4, while the stronger link was with the APOE e2/e4 genotype (Table 3 ). Among symptomatic CAA cohorts, only APOE e2/e3 and APOE e2/e4 were associated with disseminated cSS (Table 3 ). Of note, the APOE e4/e4 genotype was associated with marginally lower odds of having disseminated cSS in symptomatic CAA patients (OR: 0.24; 95%CI: 0.06-0.92, p=0.038, see Table 3 ). The statistical heterogeneity for these subanalyses ranged from low, to moderate and high (Table 3 ).
Discussion
The current meta-analysis provides a comprehensive assessment on cSS, 1 CAA, 21 and their association with APOE genotype. Drawing data from >4000 participants of relevant studies and different clinical setting, our main results indicated that cSS, especially disseminated cSS, is most strongly associated with APOE e2+ genotype. This overall association was consistent and did not vary significantly according to clinical setting. We found that APOE e4+ genotype was overall not associated with cSS presence or burden. However, APOE e4+ genotype results varied depending on the clinical setting, with memory clinic patients (but not symptomatic ICH patients) showing an association with cSS, albeit weaker compared to APOE e2+ genotype based on the unadjusted pooled ORs (2.10 versus 3.28 respectively). In the detailed subanalyses looking at individual APOE genotypes and cSS burden, the most consistent associations with higher effect sizes were seen with the e2/e2 and e2/e4 genotypes.
Although it can be challenging to infer specific pathophysiological mechanisms from genetic associations, the most straightforward and parsimonious explanation for our results is that cSS is indeed a strong and specific MRI biomarker for more advanced or active CAA.
These results confirm our prespecified hypothesis, are consistent with prior observations in the field, with what is presumed to be the effect of APOE e2 vs. e4 on underlying CAArelated vasculopathic changes, and with the emerging clinical relevance of cSS as an independent risk factor for future symptomatic ICH. APOE genotype is the single most important genetic determinant in CAA pathophysiology. 10, 11 APOE e4 appears to enhance vascular amyloid-β deposition in a dose-dependent fashion, 12 while APOE e2 promotes vasculopathic changes (vessel cracking, vessel-within-vessel appearance and fibrinoid necrosis)
which can lead to vessel rupture. 13 A previous meta-analysis investigating APOE associations with cerebral microbleeds found that strictly lobar microbleeds (a putative marker of CAA presence) was related to APOE e4 + allele (OR: 1.35, 95%CI: 1.10-1.66, p=0.005), but not APOE e2. 22 This result was consistent for any cerebral microbleeds presence in a more recent comprehensive meta-analysis. 23 The dissociation of the relationship between APOE genotype and cerebral microbleeds vs. cSS has implications for discerning potential mechanisms. APOE e4 might predispose to the particular kind of CAA-related vessel thickening postulated to lead to microscopic intraparenchymal hemorrhage (e.g. strictly lobar cerebral microbleeds). 24 In contrast, APOE e2 might promote the most severe stages or aggressive phenotype of CAA pathology that precede rupture, especially in leptomeningeal vessels, hence contributing to MRI-visible superficial CAA-related bleeds (aka cSS) in multiple spatially separated foci. 4, 20 A recent neuropathological study used a detailed grading system for assessing CAA in parenchymal and leptomeningeal vessels separately. 25 In a sample of Alzheimer's disease and non-demented elderly control brains, APOE e2 was a much stronger risk factor for CAA development, especially in leptomeningeal vessels, compared to APOE e4 (OR: 10.93; 95%CI:
4.33-27.57 vs. 1.69; 0.92-3.10, respectively). 25 Fittingly, an inverse relationship has been observed between greater lobar cerebral microbleed counts and cSS in advanced CAA, suggesting the possibility of differing CAA phenotypes that are driven in part by APOE genotype, and marked by the predominance of either cSS or CMBs MRI patterns. 4, 22 These inferences would also be in line with several clinical observations in the field.
APOE e2 is already known to be associated with CAA-related ICH, perhaps causally, 26 also predisposing to larger volumes of CAA-related bleeding. 27 cSS is independently associated with future ICH risk in CAA, both recurrent 6, 28 and first lobar ICH. 5 In fact, clinical cohorts which incorporated and investigated both cSS and strictly lobar microbleeds in relation to future ICH, demonstrated that cSS, but not microbleeds, is the strongest independent risk factor for CAA-ICH. 5, 6, 28 Also, there is preliminary evidence that APOE e4 may be associated with CAA type 1 (where CAA is found in cortical capillaries) and APOE e2 with CAA type 2
(where cerebrovascular amyloid is primarily deposited in leptomeningeal and cortical vessels sparing cortical capillaries). 29 A recent neuropathological study which validated a detailed CAA grading system showed that all individuals with the APOE e2/e2 genotype had CAA-type 2, while the APOE e4/e4 genotype was associated with CAA type 1 (OR 8.0; 95% CI 2.8-23.3). 25 Finally, though the exact pathophysiological mechanisms underlying cSS remain debatable, 1 MRI-detected cSS seems to reflect repeated episodes of superficial bleeding from CAA-laden bleeding-prone leptomeningeal vessels. 1 Thus cSS may be a strong marker of not only more severe CAA, but CAA with more fragile, rupture-prone vessels, thereby, heralding a risk of subsequent ICH. 6, 30 APOE e2 driven vascular injury in CAA, in combination with other risk factors, could influence pathways providing initiation sites for cSS and hence future lobar ICH risk.
Our study benefited from thorough ascertainment of the totality of evidence to date on the topic, within the two clinical settings in which CAA is most commonly considered. The first setting consists of patients diagnosed in stroke clinics with relatively advanced symptomatic CAA, while memory clinic patients and healthy elderly are heterogeneous participants who mostly do not have advanced CAA (instead, mild to moderate CAA commonly accompanies Alzheimer's neurodegenerative pathology in memory clinic patients).
This fact explains the much higher proportion of cSS in the symptomatic CAA group and might partly account for the different relationship with APOE e4. We note the higher frequency of APOE e4 in patients from memory clinics, at least in part, due to the relationship between this genotype and its well-known predisposition to Alzheimer's disease (instead, APOE e2 variant confers reduced risk for Alzheimer's disease and thus has lower frequency in memory clinics). 31 Similar to Alzheimer's disease, as noted above, histopathological studies
in CAA indicate that APOE e4 has an equivalent role in CAA by promoting vascular amyloidβ deposition; APOE e2 however, has a different effect -it increases vessel wall damage caused by cerebrovascular amyloid deposition. In other words, the hypothesis is that APOE e4
increases the likelihood of having CAA among memory clinic patients (identified clinically by the presence of cSS). Among symptomatic CAA patients with already advanced (or enriched in) underlying cerebrovascular amyloid deposition, it doesn't increase the likelihood of cSSin this group, APOE e2 comes into play (especially in a dose-depended and synergistic fashion with APOE e4 gene).
Our findings in the subanalyses of detailed APOE genotypes and associations with cSS presence and burden, probably account for the prevalence and differential effects of e4 and e2 in Alzheimer's disease and CAA. However, these subanalyses need to be interpreted with caution, under the prism of the following additional considerations. The relatively small sample size contributing to each subanalysis (e.g. according to clinical setting, focal or disseminated cSS etc.) and rarity of certain alleles and genotypes, resulted in wide 95% confidence intervals.
Due to the increased number of subanalyses, we run the risk of multiple comparisons. Hence, they should be considered hypothesis-generating, highlighting possible trends, effect sizes and potential mechanistic pathways to be explored in further studies on cSS. It is important to again point out that the associations between cSS presence/burden and specific APOE genotypes, require, to some extent, different interpretation in memory clinic vs. symptomatic CAA cohorts. In memory clinic patients, APOE genotype-cSS associations are driven by the presence of substantial underlying CAA pathology that is denoted by cSS. In other words, cSS in memory clinic cohorts, identifies patients with advanced CAA (i.e. beyond the mild CAA, often a common "innocent bystander" in this setting) -the known risk factor of originally developing cerebrovascular amyloid-β accumulation is APOE e4 and e2. Symptomatic 32 This and other considerations could partly explain the weak association observed between cSS presence and APOE e4 in the memory clinic cohorts. For example, both CAA and neurodegenerative pathology contribute to cognitive impairment in the elderly 33 and APOE e4 is a well-known risk factor for both cerebrovascular and parenchymal amyloid accumulation. Nevertheless, quite reassuringly, the association with APOE e2 and cSS was consistently detected in memory clinic patients and with stronger effect size than the APOE e4 association. Lastly, our meta-analysis was performed at a group level, which means that generated pooled estimates are not adjusted for any confounders that might influence the association between APOE status and cSS, including age, sex and other MRI markers of small vessel disease. It is thus possible that reported associations are overstated.
It could be argued that our unadjusted group-level meta-analysis is exploratory, providing a rough indication of likely effect sizes across populations for the APOE-cSS link, setting the scene for a more detailed individual-patient level meta-analysis. We are hoping to pursue this in the future in a large collaborative study.
Most of the symptomatic CAA cohorts suitable for meta-analysis came from a single centre. We acknowledge the potential for some overlap among these cohorts -while we do not have all the detailed data on overlapping patients, based on the different clinical setting/recruitment, clinical presentation, inclusion criteria, inception points etc., this overlap is minimal and ranges between 5-10%, as summarised in Table 1 footnote. Any potential overlap between these cohorts is random and unlikely to have affected our main results.
However, due to this limitation, our findings will benefit from further validation and updated meta-analyses. The plausible suggestion of different APOE influences on the severity and type of amyloid deposition in the vessel wall and advanced vasculopathic changes suggested in the interpretation of our current findings, are based on limited data. 34 In particular, further studies on the proposed differential effects of e4 and e2 alleles will be valuable. However, it is reasonable to provide an informed discussion based on these biological hypotheses and assumptions, in an effort to start building a pathophysiology model of cSS that could explain both clinical and research findings and help develop hypothesis-driven studies in the field.
Finally, the vascular damage pathways leading to cSS must be only partly influenced by APOE e2 as evidenced by the fact that a number of cSS cases are also found within the APOE e3/e3 genotype.
Notwithstanding these caveats, our results provide useful data to partly settle the question in favor of a link between APOE e2+ genotype and cSS in CAA. The pathophysiologic implication is that APOE e2 influences the risk of cSS through promoting the most severe stages of CAA pathology that are associated with rupture. These results are also in line with cSS being a strong hemorrhagic MRI signature in CAA and the likely "smoking gun" of bleeding risk. Future research efforts on the topic require methodologically robust, large studies adhering to current reporting standards, 1, 35 Scoring system: For each key quality indicator listed, each study got 1 point if fulfilled. For the design "Design" criterion, studies got 1 point if they were prospective (P-1) and 0 points if retrospective (R-0). For blood-sensitive MRI sequences, accounting for the different sensitivities in detecting and assessing cSS, studies got 1 point if they used susceptibility-weighted imaging (SWI-1) and 0 points if they used T2*-weighted gradient-recalled echo (T2*-GRE-0). For study sizes, studies got 0-2 points depending on the number of included patients, i.e. ≤100, 101-200 or >200 patients, respectively. The total score was calculated by adding all the points for each individual key quality indicator, thus ranging from 0 (lowest quality) to 8 (highest quality). 2 (1.20-3.32)  p=0.008   3.41 (1.13-10.3)  p=0.029   3.96 (1.85-8.51 10 (1.11, 3.99 75 (1.01, 3.03 
